We have a portfolio of five drug candidates in clinical trials or preclinical studies
Our lead clinical program, VK5211, is a novel, orally available, non-steroidal selective androgen receptor modulator, or SARM, in development for the treatment of patients recovering from non-elective hip fracture surgery. VK5211 is designed to produce the therapeutic benefits of testosterone in muscle and bone with improved safety, tolerability and patient acceptance. We have initiated a Phase 2 clinical trial with VK5211 in patients recovering from non-elective hip fracture surgery. For more information on this study please visit NCT02578095.
Our second pipeline program is focused on the development of novel small molecule agonists of the thyroid beta (TRb) receptor, VK2809 and VK0214. These novel TRb agonists are being developed for hypercholesterolemia and fatty liver disease and X-linked adrenoleukodystrophy, or X-ALD. We have initiated Phase 2 clinical development of VK 2809 in hypercholesterolemia and fatty liver disease. VK0214 is in preclinical development for X-ALD.
We are also developing VK0612, a first-in-class, orally available drug candidate for type 2 diabetes. Preliminary clinical data suggest VK0612 has the potential to provide substantial glucose-lowering effects, with an attractive safety and convenience profile.
We are also developing preclinical programs targeted at metabolic diseases and anemia.
For information on licensing opportunities, please contact Business Development at BD@vikingtherapeutics.com.